NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 15 February 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Anna Pracz Present for all items
3. Baljit Singh (Vice-chair) Present for all items
4. Dr Andrew Makin Present for all items
5. Dr Bushra Hasnie Present for all items
6. Dr Daniel Gallacher Present for all items
7. Dr Francis Drobniewski Present for all items
8. Dr Hatim Abdulhussein Present for all items
9. Dr Natalia Kunst Present for all items
10. Dr Prithwiraj Das Present for all items
11. Dr Warren Linley Present for all items
12. Gabriel Rogers  Present for all items
13. Lisa Attrill Present for all items
14. Mary Weatherstone Present for all items
15. Nigel Westwood Present for all items
16. Professor David McAllister Present for all items
17. Stella O’Brien Present for all items
18. Tony Wootton Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Richard Diaz, Associate Director Present for all items

Vonda Murray, Project Manager Present for all items

Adam Brooke, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Harsimran Sarpal, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Yelan Guo, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Summaya Mohammad, Heath Technology Assessment Analyst

Items 5.1 to 5.2.2

Wajeeha Asim, Administrator, Technology Appraisals Present for all items

External assessment group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Items 1.1 to 4.2.2

Isaac Corro Ramos, Kleijnen Systematic Reviews Items 1.1 to 4.2.2

Susan O'Meara, Kleijnen Systematic Reviews Items 1.1 to 4.2.2

Claire Rothery, York Items 5.1 to 5.2.2

Mark Simmonds, York Items 5.1 to 5.2.2

Clinical, Patient & NHS England experts present

William Drake, Consultant Physician, Clinical Expert, nominated by Merck Sharp & Dohme

Items 1.1 to 4.1.3

Patrick Maxwell, Head of the School of Clinical Medicine, Clinical Expert, nominated by, UK Kidney Association Items 1.1 to 4.1.3

Stana Bojanic, Consultant Neurosurgeon clinical expert, nominated by Merck Sharp & Dohme Items 1.1 to 4.1.3

Eamonn Maher, Professor of Medical Genetics and Genomic Medicine**,** Clinical Expert, nominated by Merck Sharp & Dohme Items 1.1 to 4.1.3

Gary Hotton, Consultant Neurologist clinical expert, nominated by Merck Sharp & Dohme

Items 1.1 to 4.1.3

Isabelle Kingston, Patient Expert, nominated by VHL Items 1.1 to 4.1.3

Kathryn Chapman, Patient Expert, nominated by VHL Items 1.1 to 4.1.3

Peter Clark, CDF Clinical Lead Items 1.1 to 4.1.3

Richard Keen, Consultant in Rheumatology and Metabolic Bone Disease, Clinical Expert, nominated by Kyowa Kirin Items 5.1 to 5.1.3

Kassim Javaid, Consultant Rheumatologist, Clinical Expert, nominated by XLH UK Items 5.1 to 5.1.3

Oliver Gardiner, Patient Expert, nominated XLH UK Items 5.1 to 5.1.3

Margarita Vidal, Patient Expert, nominated XLH UK Items 5.1 to 5.1.3

Fiona Marley, Head of Highly Specialised Commissioning at NHS England, commissioning expert Items 5.1 to 5.1.3

Sanjeev Patel, IMF Adviser for Highly Specialised Services at NHS England, commissioning expert Items 5.1 to 5.1.3

Observers present

Sinéad Peare, Chief Pharmaceutical Officer’s Clinical Fellow, Medicines Optimisation Items 1.1 to 4.2.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Alistair Patton, Mark Tanner, Peter Wheatley Price, Rhiannon Owen, Stuart Williams, Toby Smith, Vanessa Danielson, and Veline L’Esperance.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 1st February 2024.

1. **Appraisal of Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10817).
      3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley.
   2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10817>.

1. **Appraisal of Burosumab for treating X-linked hypophosphataemia in adults [ID3822]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Kyowa Kirin.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10733).
      3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Balijit Singh.
   2. Part 2 – Closed session (members of the public, clinical and patient experts, company representatives, and external assessment group representatives were asked to leave the meeting)
      1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10733>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 14th March 2024 and will start promptly at 9am.